The Question Nobody Asks Before the Session
Psychedelic safety conversations focus almost entirely on the mind — the challenging trip, the psychosis risk, the set and the setting. But psilocybin, LSD, mescaline, and MDMA are also cardiovascular agents, and for a meaningful slice of the population, the heart is the organ that decides whether a session is safe. This is increasingly not an abstract concern: the average age of people exploring psychedelics is rising, as clinical programs, state-licensed services, and curiosity-driven use draw in 50-, 60-, and 70-somethings with the conditions of age — hypertension, cardiac history, arrhythmias, medications — that the 1960s college-kid stereotype never had to consider. If you or someone you love is in that demographic, this is the post to read before the first dose.
The Acute Cardiovascular Signature
Classic serotonergic psychedelics produce a predictable acute cardiovascular pattern: increased heart rate, increased blood pressure (both modest — psilocybin trials report average elevations of roughly 10–30 mmHg systolic and 10–25 beats per minute, dose-dependent), and occasional transient cardiac arrhythmias. For a healthy young adult, this is the physiological equivalent of a brisk walk up a hill — noticeable, transient, harmless. It lasts the duration of the drug's activity and resolves as it clears.
For someone with cardiovascular disease, the arithmetic changes. A systolic surge to 180 on an atherosclerotic, hypertensive system is a different event than on a healthy 25-year-old's. Documented psychedelic-associated cardiac events — myocardial infarction, arrhythmia-driven complications — are rare in the literature but cluster predictably in older users with pre-existing risk factors, exactly as common sense and cardiology would predict. Clinical trials exclude unstable cardiac patients for precisely this reason, and the exclusion is a safety finding, not bureaucracy.
The one absolute rule that emerges from both the trial literature and harm reduction practice: anyone with significant cardiac disease, uncontrolled hypertension, a history of arrhythmia, or recent cardiac events needs physician clearance before any serotonergic psychedelic. The licensed service frameworks now operating in some jurisdictions build medical screening in for exactly this reason — and an unscreened session for a cardiac patient is the specific failure mode the screening exists to prevent.
The 5-HT2B Issue: The Slow Cardiac Risk
The acute blood-pressure story is the visible half of psychedelic cardiology. The less visible half is slower and more insidious: the 5-HT2B receptor.
Heart valves are rich in 5-HT2B receptors, which play a normal role in valve development and repair. Chronic stimulation of those receptors, however, causes fibroblasts to proliferate and deposits to build on the valves — a process called valvular heart disease. This isn't theoretical: it was the mechanism that killed the diet drug fenfluramine (half of the infamous fen-phen combination), which caused measurable valvulopathy in a subset of patients on long-term therapeutic doses. Fenfluramine is a 5-HT2B agonist. So, at varying affinities, are LSD and psilocybin.
What this means in practice is a function of exposure: single or rare full-dose sessions produce negligible 5-HT2B activation. Chronic exposure is the risk variable — and the practice that maximizes chronic exposure is microdosing: repeated sub-perceptual dosing, three or four days a week, month after month, precisely the pattern that keeps 5-HT2B receptors continuously stimulated. There is no long-term cardiac outcome data for psychedelic microdosing, but the pharmacological parallel to fenfluramine is strong enough that cardiovascular researchers flag it as the field's most plausible hidden long-term harm. A practical ceiling some harm reduction clinicians suggest: treat microdosing as a time-limited experiment (weeks, not years), and anyone with a personal or family history of valve disease should think twice entirely.
MDMA deserves separate mention: beyond 5-HT2B, it directly stresses the cardiovascular system (hypertension, tachycardia, hyperthermia) more than the classic psychedelics, and its frequent-use pattern among some users compounds everything.
Medications: The Intersection of Heart and Psychedelic
Older users are medicated users, and the intersection matters:
- Beta-blockers and antihypertensives alter the blood-pressure response unpredictably and can produce exaggerated drops when combined with the post-peak "crash" phase.
- Stimulant-adjacent combinations — anyone using decongestants, ADHD medications, or energy products alongside psychedelics is stacking sympathetic load on an already elevated cardiovascular state.
- QT-prolonging drugs (some antibiotics, antipsychotics, antiarrhythmics) combined with serotonergic agents warrant physician review, since both classes carry arrhythmia considerations at the cellular level.
- The full interaction picture — MAOIs, SSRIs, and the serotonin syndrome territory — is covered in this series' interaction post and applies in full to older, medicated users.
Practical Cardiovascular Screening Before a Session
Anyone over 50, anyone with cardiac risk factors, and anyone on cardiac medications should run this checklist with their physician before any serotonergic session — including microdosing regimens:
1. Recent blood pressure check, and a frank conversation about whether it's controlled 2. Personal history: heart attack, stroke, arrhythmia, valve disease, heart failure 3. Family history of early cardiac death or valve disease 4. Full medication and supplement list, reviewed against the substance 5. For anything beyond a single session: a view on the 5-HT2B chronic-exposure question, especially for microdosing 6. An honest assessment of fitness for the experience's physical arc — hours of lying still, possible temperature shifts, the stress of intense emotion itself (acute psychological stress is a cardiac event trigger in vulnerable people; a terrifying trip is, physiologically, a stress test)
The Bottom Line
The mind gets the attention in psychedelic safety, but the heart writes some of the exclusion criteria. Acute cardiovascular effects are modest and transient in the healthy and young; they're a genuine risk calculus in the older, the hypertensive, and the medicated. And the slow-burn 5-HT2B concern hangs over the one practice — chronic microdosing — that the culture currently markets as endlessly sustainable. The guidance converges on a simple posture: screen honestly, involve a physician when age or cardiac history enters the picture, treat microdosing as an experiment with an endpoint rather than a lifestyle, and never let enthusiasm for the frontier outrun the cardiovascular facts. These compounds are powerful. So is the heart they act upon.
